semaglutide injection Wegovy
Selected indexed studies
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. (N Engl J Med, 2021) [PMID:33567185]
- Wegovy (semaglutide): a new weight loss drug for chronic weight management. (J Investig Med, 2022) [PMID:34706925]
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. (Lancet, 2021) [PMID:33667417]
_Worker-drafted node — pending editorial review._
Connections
semaglutide injection Wegovy is a side effect of
Sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021) pubmed
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. (2021) pubmed
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. (2021) pubmed
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. (2021) pubmed
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. (2024) pubmed
- Safety of Semaglutide. (2021) pubmed
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. (2024) pubmed
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. (2022) pubmed
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. (2021) pubmed
- Wegovy (semaglutide): a new weight loss drug for chronic weight management. (2022) pubmed